← Leaderboards
Arnold L Potosky
Georgetown University
$11,589,176
Attributed
$17,550,831
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,550,831 · 8
By mechanism
U01$9,059,900 · 2
R01$7,493,478 · 5
RC1$997,453 · 1
Top collaborators
- Reina Haque7 shared
- Carol M Moinpour6 shared
- Marianne Ulcickas Yood2 shared
- Stephen K. Van Den Eeden2 shared
Most similar at Georgetown University
Same institution · by research overlap
- Janet E Audrain-McGovern$24,829,618
- Carol M Moinpour$2,858,250
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDiagnosisComorbidityCaliforniaCaringHealth Related Quality Of LifeCancer TherapyRaceNeoplasm RegistryAdultHealthcareCohortFollow-UpPainEnsureLinkOncologyPersonsChemotherapyCharacteristicsHigh RiskCancer DiagnosisNewly DiagnosedPatient Outcomes Assessments
Grant awards (28)
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$2,015,377
U01 · FY2025 · CA · contact PI
Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer$707,923
R01 · FY2025 · CA · contact PI
Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer$679,461
R01 · FY2024 · CA · contact PI
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$627,896
U01 · FY2024 · CA · contact PI
Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer$763,788
R01 · FY2023 · CA · contact PI
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$700,128
U01 · FY2023 · CA · contact PI
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$368,787
R01 · FY2023 · HL
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$375,049
R01 · FY2022 · HL
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors$274,342
R01 · FY2022 · NR · contact PI
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$378,169
R01 · FY2021 · HL
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors$353,886
R01 · FY2021 · NR · contact PI
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$411,468
R01 · FY2020 · HL
Elucidating the Prevalence, Etiology, and Trajectories of Symptom Clusters in Early Cancer Survivors$368,118
R01 · FY2020 · NR · contact PI
Impact of Genomic and Personalized Medicine in Women under 65 with Breast Cancer - Supplement$149,851
R01 · FY2016 · CA · contact PI
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer$151,394
R01 · FY2014 · CA · contact PI
Validation of PROMIS in Diverse Cancer Populations$410,000
U01 · FY2013 · AR · contact PI
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer$339,891
R01 · FY2013 · CA · contact PI
Validation of PROMIS in Diverse Cancer Populations$1,145,445
U01 · FY2012 · AR · contact PI
Outcomes of Prostate Cancer Androgen Deprivation Therapy$549,086
R01 · FY2012 · CA · contact PI
Impact Of Genomic and Personalized Medicine in Women Under 65 With Breast Cancer$391,980
R01 · FY2012 · CA · contact PI
Validation of PROMIS in Diverse Cancer Populations$1,170,445
U01 · FY2011 · AR · contact PI
Outcomes of Prostate Cancer Androgen Deprivation Therapy$574,599
R01 · FY2011 · CA · contact PI
Validation of PROMIS in Diverse Cancer Populations$1,219,213
U01 · FY2010 · AR · contact PI
Outcomes of Prostate Cancer Androgen Deprivation Therapy$655,686
R01 · FY2010 · CA · contact PI
Validation of PROMIS in Diverse Cancer Populations$539,867
U01 · FY2010 · AR · contact PI
Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer$497,496
RC1 · FY2010 · CA
Validation of PROMIS in Diverse Cancer Populations$1,231,529
U01 · FY2009 · AR · contact PI
Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate Cancer$499,957
RC1 · FY2009 · CA